For the first quarter of 2024, Bayer reported core EPS down 4.4% to 2.82 euros, EBITDA excluding non-recurring items down 1.3% to 4.41 billion euros, and free cash flow improved to -2.63 billion from -4.1 billion a year earlier.

At almost 13.8 billion euros, the German group's sales fell by 0.6% in organic terms, with decreases of 3% in agrochemicals and 1.8% in consumer health care, but an increase of 3.9% in pharmaceuticals.

Bayer confirms its currency-adjusted guidance for 2024, although a negative currency impact has led it to reduce its target range for EBITDA excluding non-recurring items from €10.4-11 billion to €10.2-10.8 billion.

Copyright (c) 2024 All rights reserved.